Wiseman H, Cannon M, Arnstein H R, Halliwell B
Biomedical Sciences Division, King's College London, Strand, U.K.
Biochem Pharmacol. 1993 May 5;45(9):1851-5. doi: 10.1016/0006-2952(93)90443-z.
Tamoxifen and 4-hydroxytamoxifen were both good inhibitors of iron-dependent lipid peroxidation in rat cardiac microsomes. Tamoxifen was also a good inhibitor of lipid peroxidation in liposomes prepared from the phospholipid obtained from rat liver microsomes. In a modified rat liver microsomal system containing a sufficiently low amount of peroxidizable phospholipid to make it comparable with the rat cardiac microsomal system, tamoxifen and 4-hydroxytamoxifen were of similar effectiveness as in the cardiac system. Tamoxifen is known to lower serum cholesterol levels, and the findings reported here indicate that the drug might also protect heart cell membranes against peroxidative damage. Potential cardioprotective and antiatherosclerotic benefits of tamoxifen are discussed in relation to the drug's use in cancer prevention and treatment.
他莫昔芬和4-羟基他莫昔芬都是大鼠心脏微粒体中铁依赖性脂质过氧化的良好抑制剂。他莫昔芬也是由大鼠肝脏微粒体制备的脂质体中脂质过氧化的良好抑制剂。在一个改良的大鼠肝脏微粒体系统中,该系统含有足够低量的可过氧化磷脂,使其与大鼠心脏微粒体系统具有可比性,他莫昔芬和4-羟基他莫昔芬的有效性与在心脏系统中相似。已知他莫昔芬可降低血清胆固醇水平,此处报道的研究结果表明,该药物还可能保护心脏细胞膜免受过氧化损伤。本文讨论了他莫昔芬在癌症预防和治疗中的应用所具有的潜在心脏保护和抗动脉粥样硬化益处。